We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Artemisinin Hastens TB Cure by Preventing Bacteria from Becoming Dormant

By LabMedica International staff writers
Posted on 05 Jan 2017
A team of microbiologists has found that a drug usually used to treat malaria can shorten the time needed to treat tuberculosis (TB) by preventing the causative organism (Mycobacterium tuberculosis) from entering a dormant, drug resistant state.

The drug, artemisinin, which is isolated from the plant Artemisia annua, a sweet wormwood, is an herb employed in Chinese traditional medicine. More...
A precursor compound can be produced using genetically engineered yeast. Artemisinin has been used for the treatment of Plasmodium falciparum related infections but low bioavailability, poor pharmacokinetic properties, and high cost of the drugs are a major drawback of their use, and there are signs that malarial parasites are developing resistance to the drug.

Investigators at Michigan State University (East Lansing, USA) examined the effectiveness of artemisinin for treatment of TB after it was identified during a screen of more than 540,000 compounds that were tested for ability to prevent M. tuberculosis from entering its dormant state.

The investigators reported in the December 19, 2016, online edition of the journal Nature Chemical Biology that M. tuberculosis became dormant in response to hypoxia, and that artemisinin inhibited the bacterial heme molecule, which functioned as an oxygen sensor. By disabling this sensor, artemisinin prevented the organism from sensing how much oxygen it was getting and blocked it from becoming dormant.

“When M. tuberculosis is starved of oxygen, it goes into a dormant state, which protects it from the stress of low-oxygen environments,” said senior author Dr. Robert Abramovitch, assistant professor of microbiology and molecular genetics at Michigan State University. “If M. tuberculosis cannot sense low oxygen, then it cannot become dormant and will die. When TB bacteria are dormant, they become highly tolerant to antibiotics. Blocking dormancy makes the TB bacteria more sensitive to these drugs and could shorten treatment times. Two billion people worldwide are infected with M. tuberculosis. TB is a global problem that requires new tools to slow its spread and overcome drug resistance. This new method of targeting dormant bacteria is exciting because it shows us a new way to kill it.”

Related Links:
Michigan State University


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Collection and Transport System
PurSafe Plus®
Capillary Blood Collection Tube
IMPROMINI M3
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.